Búsqueda de un ensayo clínico
Otra(s) opcion(es) de búsqueda
42 Resultado(s)
Ensayo clínico en reclutamiento
= 
; Ensayos clínico en curso
= 
; Financiado por un miembro del IRDiRC = 
; Miembro de una ERN = 
Ensayo(s) clínico(s) nacional(es)
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
Inhalation of Liposomal Amphotericin B to Prevent Invasive Aspergillosis
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
Weekly Aerosolized Liposomal Amphotericin B for the Prevention of Invasive Pulmonary Aspergillosis During Prolonged Neutropenia
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
Ensayo en Fase 3, abierto, aleatorio, para evaluar la eficacia y seguridad de AZLI respecto a TOBI® en un régimen antibiótico en aerosol intermitente en pacientes con fibrosis quística (US y EU), seguido de una extensión de brazo único, abierta (EU) (completado)
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
An Open-Label, randomized, phase III trial to evaluate the efficacy and safety of Aztreonam (AZLI) versus TOBI® (TNS, Tobramycin Nebuliser Solution) in an intermittent aerosolized antibiotic regimen in patients with Cystic fibrosis, followed by an open-label, single arm extension - BE.
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
ARTEMIS-IPF: Estudio en Fase 3, aleatorio, doble ciego, controlado por placebo, multicéntrico, de grupos paralelos, orientado por eventos, para evaluar la eficacia y seguridad de Ambrisentan en sujetos con principios de fibrosis pulmonar idiopática (FPI) (completado)
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
Estudio a largo plazo de Ambrisentan en sujetos con hipertensión arterial pulmonar que han finalizado el estudio AMB-320 o el AMB-321 (Fase III) (completado)
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
Estudio de dosis, en Fase 2, aleatorio, doble ciego, controlado por placebo, multicéntrico, de Cicletanine en sujetos con hipertensión arterial pulmonar (finalizado)
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
An Open-Label, Randomized, Phase 3 Trial to Evaluate the Efficacy and Safety of Aztreonam 75 mg Powder and Diluent for Nebulizer Solution (AZLI) versus Tobramycin Nebulizer Solution (TNS) in an Intermittent Aerosolized Antibiotic Regimen, in subjects with Cystic Fibrosis followed by an Open-Label, Single Arm Extension - UK (Completed)
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
Open multicenter phase III study to asses safety and efficacy of inhalatory Aztreonam Lisine versus Tobramycin solution for nebulization, in the context of a intermittent antibiotic aerosol regimen in patients with cycstic fibrosis - IT
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
A Phase 2, randomized, double-blind, placebo-controlled, multicenter, dose-ranging study of Cicletanine in subjects with Pulmonary Arterial Hypertension - DE - Prematurely Ended
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
AmBiGuard: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukemia - UK
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
AmbiGUARD - A phase 3, double-blind, multicenter, randomized, placebo controlled study to assess the efficacy, safety and tolerability of prophylactic liposomal amphotericin B (AmBisome®) for the prevention of invasive fungal infections (IFIs) in subjects receiving remission induction chemotherapy for acute lymphoblastic leukemia (ALL) - FR
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
Ensayo abierto en Fase 3 para evaluar la seguridad de Aztreonam 75 mg en polvo y disolvente para solución para inhalación por nebulizador (AZLI) en niños con fibrosis quística e infección crónica en las vías respiratorias bajas por pseudomonas aeruginosa (PA) (completado)
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
DELTA: A Phase 2 study to assess the efficacy and safety of CAL-101 in patients with indolent B-Cell Non-Hodgkin Lymphoma refractory to Rituximab and alkylating agents - DE
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
AmBiGuard: A Phase 3, double-blind, multicentre, randomized, placebo-controlled study to assess the efficacy, safety and tolerability of Liposomal Amphotericin B (AmBisome®) for the prevention of Invasive Fungal Infections (IFIs) in subjects receiving remission-induction chemotherapy for Acute Lymphoblastic Leukemia - DE- Completed
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
ALPINE: Open-Label phase II trial to evaluate the safety and efficacy of Aztreonam in pediatric patients with Cystic Fibrosis (CF) and new onset lower respiratory tract culture positive for Pseudomonas Aeruginosa (PA) - DE - Completed
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
PALS: Open-Label phase III trial to evaluate the safety of Aztreonam in children with Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa (PA) in the lower airways -DE- Completed
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
Estudio de fase 3, aleatorizado, doble ciego, controlado con placebo para evaluar la eficacia y la seguridad de GS-1101 (CAL-101) en combinación con bendamustina y rituximab para la leucemia linfocítica crónica tratada previamente (finalizado)
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
Estudio de Fase 3, aleatorizado, controlado para evaluar la eficacia y seguridad de GS-1101 (CAL-101) en combinación con ofatumumab para el tratamiento de la leucemia linfocítica crónica previamente tratada (completado)
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
RAINIER (GS-US-322-0207): A Phase 2, randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of Simtuzumab (GS-6624) in subjects with Idiopathic Pulmonary Fibrosis - DE
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination with Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia - UK
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
NCRN389: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia - UK
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
NCRN539: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas - UK
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
NCRN474: A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia - UK
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
NCRN474: A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia - IE
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
NCRN389: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia - FR
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
NCRN538: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for previously Treated Indolent Non-Hodgkin Lymphomas - UK
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de idelalisib (GS-1101) en combinación con rituximab en linfomas no Hodgkin indolentes previamente tratados (finalizado)
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
Estudio de fase III, aleatorizado, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de idelalisib (GS-1101) en combinación con bendamustina y rituximab en linfomas no Hodgkin indolentes previamente tratados (finalizado)
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
AmBiGuard: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukemia (ALL) - AT
Gilead Sciences International Limited
Ensayo(s) clínico(s) multinacional(es)
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
Open-Label Phase 3 Trial to Evaluate the Safety of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Children With Cystic Fibrosis (CF) and Chronic Pseudomonas Aeruginosa (PA) in the Lower Airways (Coordination)
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia - Coordination
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
AmBiGuard: A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Study to Assess the Efficacy, Safety and Tolerability of Prophylactic Liposomal Amphotericin B (AmBisome®) for the Prevention of Invasive Fungal Infections (IFIs) in Subjects Receiving Remission-Induction Chemotherapy for Acute Lymphoblastic Leukemia
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
ALPINE: Open-Label Phase 2 Trial to Evaluate the Safety and Efficacy of Aztreonam 75 mg Powder and Solvent for Nebuliser Solution/Aztreonam for Inhalation Solution (AZLI) in Pediatric Patients With Cystic Fibrosis (CF) and New Onset Lower Respiratory Tract Culture Positive for Pseudomonas Aeruginosa (PA)
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
NCRN389: A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS-1101) in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
A Phase 3, Randomized, Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination With Ofatumumab for Previously Treated Chronic Lymphocytic Leukemia
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of GS-1101 (CAL-101) in Combination with Rituximab for previously Treated Indolent Non-Hodgkin Lymphomas
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib (GS 1101) in Combination with Bendamustine and Rituximab for Previously Treated Indolent Non-Hodgkin Lymphomas
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE
Open multicenter phase III study to asses safety and efficacy of inhalatory Aztreonam Lisine versus Tobramycin solution for nebulization, in the context of a intermittent antibiotic aerosol regimen in patients with cycstic fibrosis.
Gilead Sciences International Limited
REINO UNIDO (EL)
Cambridgeshire
CAMBRIDGE